Drug
Ofirnoflast
Ofirnoflast: highest development phase Phase 2, developed by Halia Therapeutics, Inc.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Halia Therapeutics, Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ofirnoflast NCT07738510 | Phase 2 | Myelodysplastic Syndromes |
Latest
No recent events.
Follow Ofirnoflast on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.